- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Neeraj Agarwal on Who Can Benefit from PARP Inhibition
Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, shares his experience regarding the prostate cancer patients who could potentially benefit from PARP inhibition.
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, shares his experience regarding the prostate cancer patients who could potentially benefit from PARP inhibition.
Transcript
In your opinion, who is an appropriate candidate for a PARP inhibitor in prostate cancer?
Everyone who has a DNA repair gene defect, or homologous recombination repair defect, is a candidate for treatment with a PARP inhibitor. If we don't identify these patients, we are offering them the alternate treatment, which is chemotherapy. And we know from multiple data sets, larger real world data sets such as flat RM, for example, the real world use of chemotherapy is very low in patients with metastatic castrate-resistant prostate cancer, which basically tells us that our patients in the real world are not really eligible or enthusiastic about receiving chemotherapy in castrate-resistant prostate cancer. How to make them eligible and to maximize eligibility for treatment with PARP inhibitors is the most important question, which can only be answered by testing all our patients to look for these mutations.
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer
February 18th 2024Despite socioeconomic and biological differences that contribute to disparities between Black men and White men with prostate cancer, improved access has been shown to reduce the gaps, explained Jun Gong, MD, of Cedars Sinai.
Read More
Surgery, Radiation for PCa Show Equal Efficacy in Candidates for Renal Transplantation
September 27th 2023A recent study suggests that patients with high-risk prostate cancer (PCa) in need of renal transplantation should receive cancer treatment before their transplants, as surgery and radiation treatment for localized PCa appear to be equally effective in this patient population.
Read More
Racial Differences in Chemokine Expression May Contribute to Prostate Cancer Disparities
September 22nd 2023Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate cancer treatment.
Read More
Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC
September 16th 2023Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.
Read More
Expert Panel Addresses Prostate Cancer Misconceptions, Importance of Screening
September 14th 2023Panelists from the American College of Surgeons (ACS) and the American Urological Association spread awareness about the realities of prostate cancer, the importance of screening, and ways for men to approach their health concerns and prevention.
Read More
Adaptive SBRT May Reduce GU/GI Toxicity Risk in Prostate Cancer
September 8th 2023A meta-analysis found that the use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) correlated with fewer acute grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicities compared with CT-guided non-adaptive SBRT in patients with prostate cancer.
Read More
